• home rotate text1
  • home rotate text2
  • home rotate text3

NeoChord, Inc.

A venture backed medical device company, is investigating minimally invasive technology intended to transform the treatment of mitral regurgitation.  The company has an exclusive worldwide license to the technology and is currently working on additional minimally invasive technologies for the treatment of structural heart disease.
-Learn More-

Latest Developments and Events

  • NeoChord Crosses 100th Patient Milestone; Appoints Michael Dale to Board of Directors
    April 4, 2014
    - Click for Release -

  • NeoChord successful live case performed at EACTS.
    Nov. 5, 2013

  • NeoChord holds first Scientific Advisory Board (SAB) meeting.
    Nov. 5, 2013
    - Click for More News -

What The Experts Are Saying

"There is a compelling need for less invasive mitral repair technologies."
"NeoChord has developed a mitral valve repair technology that may offer MR patients the choice of a minimally invasive procedure over the current standard-of-care: open-chest surgery on a stopped heart" says Giovanni Speziali, M.D., Cardiac Surgeon and primary inventor of the Neochord Device.
- Click to Learn More -